Addressing the needs of childhood cancer survivors
Most children and adolescents diagnosed with cancer will survive. This means the number of childhood cancer survivors in Canada and around the world is growing. Unfortunately, many of the treatments we use to cure cancer can lead to long-term physical and mental health problems known as “late effects”. Childhood cancer survivors need lifelong follow-up care that is focused on their risks for late effects. This follow-up care will allow survivors to stay healthy and have the best quality of life possible. Our research team is focused on understanding these long-term risks and finding ways to make sure that all survivors receive the health care and other supports that they need.
Addressing the needs of adolescents and young adults with cancer
Adolescents and young adults (AYA; aged 15-39 years) are a particularly vulnerable group of cancer patients – their cancer outcomes have not improved as much as younger children and older adults. Our research program also uses Ontario’s health administrative databases and cancer registries to study outcomes in AYA with cancer from diagnosis through treatment to survivorship.
Get to know Dr. Paul Nathan
Addressing the needs of childhood cancer survivors
Most children and adolescents diagnosed with cancer will survive. This means the number of childhood cancer survivors in Canada and around the world is growing. Unfortunately, many of the treatments we use to cure cancer can lead to long-term physical and mental health problems known as “late effects”. Childhood cancer survivors need lifelong follow-up care that is focused on their risks for late effects. This follow-up care will allow survivors to stay healthy and have the best quality of life possible. Our research team is focused on understanding these long-term risks and finding ways to make sure that all survivors receive the health care and other supports that they need.
Addressing the needs of adolescents and young adults with cancer
Adolescents and young adults (AYA; aged 15-39 years) are a particularly vulnerable group of cancer patients – their cancer outcomes have not improved as much as younger children and older adults. Our research program also uses Ontario’s health administrative databases and cancer registries to study outcomes in AYA with cancer from diagnosis through treatment to survivorship.
Recent Publications
Late effects after high-risk neuroblastoma (LEAHRN): a multicentre, cross-sectional cohort study from the Children's Oncology Group
Outcomes after solid organ transplantation in survivors of childhood, adolescent, and young adult cancer: a population-based study
Physical morbidities in survivors of testicular germ cell tumors during childhood, adolescence, and young adulthood: a population-based retrospective matched cohort study
Longitudinal adherence to surveillance for late effects of cancer treatment: a population-based study of adult survivors of childhood cancer
The medical and functional burden of surviving childhood ependymoma: A population-based study in Ontario, Canada
Utility of a cancer predisposition screening tool for predicting subsequent malignant neoplasms in childhood cancer survivors.
Recent Publications
Late effects after high-risk neuroblastoma (LEAHRN): a multicentre, cross-sectional cohort study from the Children's Oncology Group
Outcomes after solid organ transplantation in survivors of childhood, adolescent, and young adult cancer: a population-based study
Physical morbidities in survivors of testicular germ cell tumors during childhood, adolescence, and young adulthood: a population-based retrospective matched cohort study
Longitudinal adherence to surveillance for late effects of cancer treatment: a population-based study of adult survivors of childhood cancer
Source: Pediatric Oncology Group of Ontario. Childhood Cancer in Ontario: The 2020 POGO Surveillance Report. Toronto: Pediatric Oncology Group of Ontario; 2020. For more information about the burden of childhood cancer in Ontario, including statistics related to childhood cancer incidence, mortality, survival and prevalence, please see the POGO Surveillance Report.

